Lack of support for bexarotene as a treatment for Alzheimer's disease.
O'Hare E, Jeggo R, Kim EM, Barbour B, Walczak JS, Palmer P, Lyons T, Page D, Hanna D, Meara JR, Spanswick D, Guo JP, McGeer EG, McGeer PL, Hobson P.
O'Hare E, et al. Among authors: walczak js.
Neuropharmacology. 2016 Jan;100:124-30. doi: 10.1016/j.neuropharm.2015.04.020. Epub 2015 May 27.
Neuropharmacology. 2016.
PMID: 26025659
Free article.